Decoding anemoside B4: Core mechanistic axes and an omics-to-atom paradigm

Anemoside B4 (AB4), a prominent triterpenoid saponin from Pulsatilla chinensis, has advanced to NMPA-approved clinical trials for ulcerative colitis. Despite its robust macroscopic efficacy across inflammatory, oncological, viral, and metabolic landscapes, its precise molecular wiring remains fragmented. Here, we distill AB4's pleiotropic actions into four core mechanistic axes: upstream pattern-recognition receptor (PRR) sensing, cell-fate trajectory control, immunometabolic coupling, and antiviral innate immune amplification. Critically, we identify a fundamental "context-dependency paradox"-exemplified by AB4's stringent suppression of the PI3K/Akt pathway in malignancies versus its forceful activation in diabetic skeletal muscle. We posit that this paradoxical bidirectional regulation is an artifact of the "resolution ceiling" imposed by traditional bulk-tissue analyses, which inherently mask cell-type-specific interactomes. To transcend this bottleneck, we propose a transformative "Omics-to-Atom" paradigm. By integrating single-cell/spatial transcriptomics, cell-type-specific chemoproteomics, cryo-electron microscopy (Cryo-EM), and CRISPR-based functional genomics, this framework dissects cellular heterogeneity to reveal dynamic, context-specific drug-protein assemblies. Ultimately, this paradigm not only clarifies AB4's mechanism for patient stratification and proactive safety prediction but also provides a scalable blueprint for modernizing natural product pharmacology into precision medicine.